StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
15
This year
1
Publishing Date
2024 - 01 - 30
1
2023 - 05 - 03
1
2023 - 04 - 27
1
2023 - 03 - 10
1
2023 - 02 - 10
1
2022 - 08 - 03
1
2022 - 07 - 27
1
2022 - 06 - 03
1
2022 - 04 - 12
1
2022 - 03 - 29
1
2022 - 02 - 01
1
2021 - 08 - 17
1
2021 - 07 - 26
1
2021 - 04 - 22
1
2020 - 12 - 17
1
Sector
Consumer non-durables
1
Health technology
15
Manufacturing
2
Process industries
1
Tags
Active
2
Approval
10
Bio-nc
1
Breast
1
Breast cancer
1
Cancer
4
Dostarlimab
2
Drug
2
Expected
2
Fda
8
Fda approval
2
Fda-approvals
2
Genomics
1
Grant
1
Granted
1
Grants
1
Group
1
Growing
1
Growth
5
Health
1
Hiv
3
Hypertension
1
Infections
1
Lipodystrophy
1
Lupus
2
Market
6
N/a
9
News
1
Order
1
Pharm-country
1
Pipeline
1
Product-news
1
Profitable
1
Report
3
Research
1
Respiratory
1
Service
1
Services
1
Solid tumors
1
System
1
Thc
1
Therapeutics
3
Treatment
3
Trial
1
Vaccine
1
Virus
2
Women
1
Entities
Abbvie inc.
4
Acadia pharmaceuticals inc.
1
Adc therapeutics sa
1
Agenus inc.
1
Albemarle corporation
1
Amgen inc.
2
Anaptysbio, inc.
1
Astrazeneca plc
4
Biogen inc.
1
Bristol-myers squibb company
1
Cti biopharma corp.
1
Eli lilly and company
3
Glaxosmithkline plc
15
Johnson & johnson
3
Neurocrine biosciences, inc.
1
Neuropace inc
1
Novartis ag
4
Perrigo company
1
Pfizer, inc.
3
Puma biotechnology inc
1
Reckitt benckiser group plc
1
Sanofi
5
Teva pharmaceutical industries ltd
5
Viatris inc.
1
Symbols
ABBV
58
ABT
61
ADCT
20
ADMA
18
AGIO
12
ALNY
13
AMGN
31
AMRX
17
ANIP
19
ARVL
24
AVEO
22
AZN
19
BCRX
16
BGNE
34
BIIB
26
BMY
60
BPMC
24
CALT
12
CLVS
20
CNSP
13
EPZM
19
EXEL
14
FNCTF
49
FRG
16
FST
13
GH
12
GILD
27
GSK
15
ILMN
13
IMMX
12
INCY
52
JAGX
16
JNJ
196
KMDA
16
KPTI
32
LLY
79
LTUM
15
MDT
35
MRK
52
MRNA
13
MS
21
NBR
19
NVAX
15
NVO
13
NVS
39
NVSEF
31
PAC
12
PFE
58
PRGO
62
REGN
69
RIGL
12
SNY
225
SNYNF
176
TAK
35
TEVJF
28
TMO
15
VRTX
12
VSAC
16
WGO
13
YMAB
21
Exchanges
Nasdaq
10
Nyse
15
Crawled Date
2024 - 01 - 30
1
2023 - 05 - 03
1
2023 - 04 - 28
1
2023 - 03 - 10
1
2023 - 02 - 10
1
2022 - 08 - 03
1
2022 - 07 - 27
1
2022 - 06 - 03
1
2022 - 04 - 12
1
2022 - 03 - 29
1
2022 - 02 - 01
1
2021 - 08 - 17
1
2021 - 07 - 26
1
2021 - 04 - 22
1
2020 - 12 - 17
1
Crawled Time
00:00
1
04:00
1
06:00
1
08:00
1
14:00
1
14:12
1
14:30
1
17:00
1
18:00
2
20:00
1
21:00
2
23:00
2
Source
www.biospace.com
6
www.prnewswire.com
9
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
approved
symbols :
Gsk
save search
Breast Cancer Therapeutics Market 2023, USD 15.64 billion Growth is Expected between 2023 to 2028, Robust pipeline and new drug approvals to Boost Growth - Technavio
Published:
2024-01-30
(Crawled : 18:00)
- prnewswire.com
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
5.21%
|
O:
5.68%
H:
0.77%
C:
0.77%
AZNCF
|
News
|
$136.2
-4.19%
1.7K
|
Health Technology
|
5.7%
|
O:
3.41%
H:
0.0%
C:
-2.45%
VTRS
|
News
A
|
$11.235
-0.13%
-0.13%
5.1M
|
Health Technology
|
-4.74%
|
O:
-0.08%
H:
3.47%
C:
-0.25%
NVS
|
News
|
$95.12
0.81%
-1.18%
2.4M
|
Health Technology
|
-12.05%
|
O:
-2.04%
H:
0.19%
C:
-1.97%
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
3.84%
|
O:
4.04%
H:
1.57%
C:
-3.02%
ABBV
|
News
|
$167.89
0.89%
0.0%
5.6M
|
Health Technology
|
1.8%
|
O:
0.5%
H:
0.07%
C:
-0.81%
SNY
|
News
|
$47.125
1.78%
1.75%
2.1M
|
Health Technology
|
-7.95%
|
O:
1.75%
H:
0.0%
C:
0.0%
PBYI
|
$5.17
3.19%
3.09%
270K
|
Health Technology
|
8.5%
|
O:
-0.1%
H:
2.31%
C:
-1.26%
AZN
|
News
|
$70.12
2.29%
2.24%
4.8M
|
Health Technology
|
4.36%
|
O:
0.82%
H:
0.12%
C:
-1.64%
AMGN
|
News
|
$271.98
1.13%
1.12%
2.1M
|
Health Technology
|
-13.58%
|
O:
0.44%
H:
0.2%
C:
-0.55%
drug
breast
expected
cancer
pipeline
therapeutics
growth
market
US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
Published:
2023-05-03
(Crawled : 23:00)
- biospace.com/
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
11.66%
|
O:
1.24%
H:
1.14%
C:
0.11%
AGEN
A
|
$5.78
8.85%
7.97%
900K
|
Health Technology
|
309.22%
|
O:
1.42%
H:
6.99%
C:
4.2%
fda
vaccine
respiratory
virus
Non-steroidal Anti-inflammatory Drugs Market Report 2023: Quick Authority Approvals by Governments and Increase in Government Initiatives Presents Opportunities
Published:
2023-04-27
(Crawled : 00:00)
- prnewswire.com
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
14.69%
|
O:
0.23%
H:
0.0%
C:
0.0%
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-16.75%
|
O:
-1.21%
H:
0.12%
C:
-2.76%
AZNCF
|
News
|
$136.2
-4.19%
1.7K
|
Health Technology
|
-4.98%
|
O:
-0.41%
H:
0.79%
C:
0.79%
RBGLY
|
News
|
$10.35
-2.05%
500K
|
Manufacturing
|
-33.81%
|
O:
2.25%
H:
0.31%
C:
0.06%
PRGO
|
$30.06
-2.4%
0.0%
1.4M
|
Health Technology
|
-17.94%
|
O:
0.11%
H:
1.61%
C:
1.42%
JNJ
|
News
|
$149.12
0.82%
0.0%
9.3M
|
Health Technology
|
-8.52%
|
O:
-0.12%
H:
0.58%
C:
0.55%
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
12.72%
|
O:
-0.25%
H:
0.97%
C:
0.31%
LLY
|
News
|
$731.33
0.69%
0.0%
2.3M
|
Health Technology
|
87.35%
|
O:
1.96%
H:
1.59%
C:
-0.54%
SNY
|
News
|
$47.125
1.78%
1.75%
2.1M
|
Health Technology
|
-16.97%
|
O:
-2.09%
H:
0.0%
C:
0.0%
AZN
|
News
|
$70.12
2.29%
2.24%
4.8M
|
Health Technology
|
-4.95%
|
O:
-1.03%
H:
1.02%
C:
0.28%
report
market
Diffuse large B-cell lymphoma (DLBCL) therapeutics market size to increase by USD 2,061.88 million between 2022 and 2027; Growth driven by increasing approval of therapeutics - Technavio
Published:
2023-03-10
(Crawled : 23:00)
- prnewswire.com
AMGN
|
News
|
$271.98
1.13%
1.12%
2.1M
|
Health Technology
|
Email alert
Add to watchlist
CTIC
|
$9.09
0.05%
11M
|
Health Technology
|
Email alert
Add to watchlist
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
Email alert
Add to watchlist
ABBV
|
News
|
$167.89
0.89%
0.0%
5.6M
|
Health Technology
|
Email alert
Add to watchlist
NVSEF
|
News
|
$93.6375
6.88%
82K
|
Health Technology
|
Email alert
Add to watchlist
NVS
|
News
|
$95.12
0.81%
-1.18%
2.4M
|
Health Technology
|
Email alert
Add to watchlist
TEVJF
|
News
|
$12.37
-24.22%
380
|
Health Technology
|
Email alert
Add to watchlist
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
Email alert
Add to watchlist
ADCT
|
$4.69
-0.64%
0.0%
170K
|
Health Technology
|
Email alert
Add to watchlist
approval
therapeutics
growth
market
US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer
Published:
2023-02-10
(Crawled : 08:00)
- prnewswire.com
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
9.73%
|
O:
-2.43%
H:
0.66%
C:
0.66%
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
11.42%
|
O:
-1.07%
H:
0.06%
C:
-0.55%
ANAB
|
$19.655
-1.08%
-1.09%
140K
|
Health Technology
|
-24.24%
|
O:
0.04%
H:
1.27%
C:
-0.62%
treatment
fda
grants
approval
cancer
Neurologic Disorders Therapeutics Market Size to Grow by USD 33.46 billion, Approval Of Novel Drugs to Boost Market Growth - Technavio
Published:
2022-08-03
(Crawled : 04:00)
- prnewswire.com
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
-2.75%
|
O:
-1.8%
H:
0.2%
C:
0.0%
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-8.03%
|
O:
-2.6%
H:
0.0%
C:
-0.76%
NPCE
|
$13.98
0.0%
130K
|
Manufacturing
|
142.63%
|
O:
0.52%
H:
3.71%
C:
-2.93%
NVS
|
News
|
$95.12
0.81%
-1.18%
2.4M
|
Health Technology
|
11.42%
|
O:
0.11%
H:
0.31%
C:
-0.34%
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
-1.43%
|
O:
-0.29%
H:
0.24%
C:
-0.58%
ABBV
|
News
|
$167.89
0.89%
0.0%
5.6M
|
Health Technology
|
18.88%
|
O:
0.32%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.125
1.78%
1.75%
2.1M
|
Health Technology
|
-6.64%
|
O:
-0.17%
H:
0.12%
C:
-1.29%
BIIB
|
$194.1
-0.14%
-0.15%
1.1M
|
Health Technology
|
-7.19%
|
O:
0.41%
H:
3.35%
C:
1.71%
ACAD
|
News
|
$17.0
1.07%
1.06%
1.2M
|
Health Technology
|
13.19%
|
O:
2.47%
H:
2.8%
C:
-2.67%
approval
therapeutics
growth
market
GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis
Published:
2022-07-27
(Crawled : 20:00)
- biospace.com/
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
-4.54%
|
O:
-0.56%
H:
3.36%
C:
2.98%
fda
active
lupus
approval
Global Panic Disorders Market Insights | Size | Shares | Trends | Growth | Industry Analysis [2020-2030] Panic disorders, also known as anxiety disorder deals with recurrent and unexpected panic attacks. PET-CT Scanner Devices Market: Competitive Landscape Analysis With Forecast by 2031 Wilmington, Delaware: According to the report, the global PET-CT scanner devices market was valued over US$ 200 Mn in 2020 and is projected to expand at a CAGR of ~3% from 2021 to 2031. Portal Hypertension Market Insights | Current Trends | Growth Opportunity | Global Industry Analysis [2020-2030] At present, treatment options for portal hypertension is limited due to the dearth of approval of specialized drugs. Spatial Genomics & Transcriptomics Market to Experience Significant Growth by 2027 Wilmington, Delaware: The spatial genomics & transcriptomics market is prognosticated to bring profitable growth during the assessment period of 2019-2027. Teleradiology Services Market to Make Great Impact in Near Future by 2031 Wilmington, Delaware: According to the report, the global teleradiology services market was valued over US$ 6.4 Bn in 2020. Anti-depressants Drugs and Therapies Market to Witness a Pronounce Growth by 2025 Wilmington, Delaware: Anti-depressants medications lower the symptoms of depression, dysthymia, chronic depression, and anxiety disorders. B-Cell Non-Hodgkin’s Lymphoma (NHL) Market to Offer Ample Growth Opportunities by 2027 Wilmington, Delaware: Non-Hodgkin’s lymphoma is a group of heterogeneous proliferative malignancies. Heightening Healthcare Spending Opening Growth Avenues for Collateral Ligament Stabilizer System Market, Reaching US$ 3.5 Billion in 2032: Fact.MR Study Fact.MR – A Market Research and Competitive Intelligence Provider: The global collateral ligament stabilizer system market is expected to reach US$ 3.5 Billion by the end of the 2022-2032 forecast period, growing at a CAGR of 6.1%, concludes a recently published report by Fact.MR. Breast Cancer Liquid Biopsy Market Trends, Growth, Analysis and Future Scope, 2026 Wilmington, Delaware: A biopsy is a tissue or cell sample taken from any part of the patient’s body and examined in the lab for the detection of cancer. Cerebral Palsy Market Size, Shares, Trends and Growth | Global Industry Analysis [2020-2030] The global cerebral palsy market is picking up steam due to increasing awareness about the condition amongst parents. Continuous Glucose Monitoring Market: Competitive Research and Precise Outlook 2021 to 2028 Wilmington, Delaware: The global continuous glucose monitoring market depicts the presence of a large competitive vendor landscape, says Transparency Market Research on the basis of a newly research report. Crow’s Feet Market Key Trends and Opportunity Analysis up to 2026 Albany NY, United States: The demand within the global crow’s feet market has been escalating on account of vital advancements in the field of dermatology in recent times. HIV Associated Lipodystrophy Syndrome Market Insights | Global Industry Analysis [2020-2030] HIV-associated lipodystrophy is a syndrome that are found in human immune-deficiency virus -infected patients who are being administered with active antiretroviral medications for the treatment of HIV infection. Global Mail Service Pharmacy Market | Size | Shares | Trends | Growth | Forecast [2020-2030]
Published:
2022-06-03
(Crawled : 06:00)
- biospace.com/
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
-23.94%
|
O:
-1.55%
H:
0.0%
C:
0.0%
SNYNF
|
News
|
$92.7
-2.18%
600K
|
Health Technology
|
-13.16%
|
O:
-0.94%
H:
0.0%
C:
0.0%
AZNCF
|
News
|
$136.2
-4.19%
1.7K
|
Health Technology
|
7.78%
|
O:
-0.4%
H:
4.05%
C:
-1.35%
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-49.79%
|
O:
0.57%
H:
0.0%
C:
0.0%
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
-6.11%
|
O:
-0.14%
H:
0.0%
C:
0.0%
LLY
|
News
|
$731.33
0.69%
0.0%
2.3M
|
Health Technology
|
135.91%
|
O:
-2.25%
H:
0.0%
C:
0.0%
BMY
|
$49.14
0.43%
0.0%
7.9M
|
Health Technology
|
-34.89%
|
O:
-1.4%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.125
1.78%
1.75%
2.1M
|
Health Technology
|
-13.75%
|
O:
-0.09%
H:
0.0%
C:
0.0%
NBIX
|
News
M
|
$133.5
1.14%
1.12%
570K
|
Health Technology
|
45.16%
|
O:
2.29%
H:
0.0%
C:
0.0%
AZN
|
News
|
$70.12
2.29%
2.24%
4.8M
|
Health Technology
|
5.47%
|
O:
-0.56%
H:
0.82%
C:
-0.64%
lipodystrophy
treatment
research
system
active
services
report
service
growing
hiv
profitable
hypertension
genomics
expected
virus
approval
cancer
growth
group
market
breast cancer
infections
Global Pharmaceutical API Manufacturing Market Report 2022-2030: Stringent Regulations for Approval of Pharmaceutical Drugs Restraining Growth
Published:
2022-04-12
(Crawled : 17:00)
- prnewswire.com
AZNCF
|
News
|
$136.2
-4.19%
1.7K
|
Health Technology
|
0.57%
|
O:
-0.86%
H:
1.21%
C:
1.21%
NVSEF
|
News
|
$93.6375
6.88%
82K
|
Health Technology
|
24.93%
|
O:
0.16%
H:
0.22%
C:
0.22%
NVS
|
News
|
$95.12
0.81%
-1.18%
2.4M
|
Health Technology
|
1.09%
|
O:
-0.48%
H:
0.09%
C:
-0.68%
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
-13.55%
|
O:
-0.36%
H:
0.0%
C:
0.0%
LLY
|
News
|
$731.33
0.69%
0.0%
2.3M
|
Health Technology
|
136.71%
|
O:
-0.77%
H:
0.99%
C:
0.49%
ALB
|
News
|
$112.29
0.13%
0.0%
2.3M
|
Process Industries
|
-45.49%
|
O:
1.31%
H:
2.06%
C:
-1.76%
ABBV
|
News
|
$167.89
0.89%
0.0%
5.6M
|
Health Technology
|
-1.14%
|
O:
-0.31%
H:
0.74%
C:
-1.18%
SNY
|
News
|
$47.125
1.78%
1.75%
2.1M
|
Health Technology
|
-20.05%
|
O:
-3.25%
H:
0.0%
C:
0.0%
AZN
|
News
|
$70.12
2.29%
2.24%
4.8M
|
Health Technology
|
-0.71%
|
O:
-2.32%
H:
0.43%
C:
-0.55%
report
approval
growth
market
drug
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living With HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg
Published:
2022-03-29
(Crawled : 18:00)
- biospace.com/
GLAXF
|
News
|
$20.2
-14.18%
510
|
Health Technology
|
-5.41%
|
O:
-0.28%
H:
0.0%
C:
-1.87%
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-50.71%
|
O:
1.35%
H:
0.15%
C:
-2.33%
JNJ
|
News
|
$149.12
0.82%
0.0%
9.3M
|
Health Technology
|
-15.56%
|
O:
1.05%
H:
0.0%
C:
0.0%
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
-6.5%
|
O:
1.17%
H:
0.0%
C:
0.0%
fda
approval
hiv
order
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment
Published:
2022-02-01
(Crawled : 14:30)
- biospace.com/
PFE
|
News
A
|
$26.26
1.0%
-0.08%
36M
|
Health Technology
|
-50.16%
|
O:
0.09%
H:
0.8%
C:
0.63%
JNJ
|
News
|
$149.12
0.82%
0.0%
9.3M
|
Health Technology
|
-12.98%
|
O:
0.22%
H:
0.0%
C:
0.0%
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
-9.4%
|
O:
0.45%
H:
0.53%
C:
0.42%
treatment
fda
health
fda approval
thc
approval
hiv
GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors
Published:
2021-08-17
(Crawled : 21:00)
- prnewswire.com
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
-4.11%
|
O:
0.17%
H:
0.66%
C:
-0.59%
fda
solid tumors
approval
dostarlimab
Shingrix approved in the US for prevention of shingles in immunocompromised adults
Published:
2021-07-26
(Crawled : 14:00)
- prnewswire.com
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
2.73%
|
O:
-0.84%
H:
0.17%
C:
-0.41%
FDA grants accelerated approval for GSK's JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
Published:
2021-04-22
(Crawled : 21:00)
- biospace.com/
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
6.12%
|
O:
-1.15%
H:
0.36%
C:
-0.34%
fda
women
cancer
trial
approval
granted
grant
dostarlimab
FDA approves GSK's BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US
Published:
2020-12-17
(Crawled : 14:12)
- prnewswire.com
GSK
|
News
|
$40.59
2.11%
-0.36%
3.8M
|
Health Technology
|
10.06%
|
O:
1.44%
H:
0.16%
C:
-0.19%
fda
lupus
fda approval
Gainers vs Losers
75%
25%
Top 10 Gainers
MTTR
|
News
M
|
$4.78
174.71%
63.6%
72M
|
AGBA
|
$2.565
105.2%
51.27%
200M
|
Finance
MLEC
|
$2.44
74.29%
42.62%
78M
|
n/a
EDBL
|
News
|
$6.28
67.02%
40.13%
16M
|
ATGL
|
$2.91
48.81%
32.8%
180K
|
ZAPP
|
$0.2175
47.16%
32.05%
16M
|
n/a
ONFO
|
$0.6075
38.38%
27.74%
7.3M
|
n/a
VIVK
|
$1.48
38.32%
27.7%
530K
|
Professional, Scientific, and T...
MNTS
|
$0.5
35.69%
26.3%
4.8M
|
SDIG
A
|
$3.635
35.13%
26.0%
1M
|
Your saved searches
Save your searches and get alerts when important news are released.